carmustine has been researched along with Disease Models, Animal in 69 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Considering the carcinogenesis model, we conclude that 2 or 4 weeks of N-nitroso-tris-chloroethylurea treatment may be suitable for investigating new chemicals for promotional or suppressive effects on lung squamous cell carcinoma." | 5.39 | Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice. ( Fujioka, M; Ishii, N; Kakehashi, A; Kitano, M; Tago, Y; Wanibuchi, H; Wei, M; Yamano, S, 2013) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 5.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| " The best dose (product of 4x10(6) cells) of TF was also combined with carmustine for experimental therapy in rats with C6 malignant glioma." | 3.73 | Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. ( Arrieta, O; Estrada-Parra, S; Pedraza-Medina, B; Pérez, R; Pineda, B; Rodriguez-Ropon, A, 2005) |
| "Comparative studies were carried out to evaluate the cytotoxic effectiveness of the nitrosureas ACNU (Nimustine) and BCNU (Carmustine) at equitoxic dose levels in xenografts from two astrocytomas grades III/IV (Li, Re) and one oligodendroglioma grade III (Oe) on nude mice." | 3.67 | Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas. ( Bamberg, M; Budach, V; Gerhard, L; Stuschke, M, 1988) |
| "Lung cancer is the leading cause of cancer-related deaths, and squamous cell carcinoma (SCC) is one of the most common types of lung cancer." | 1.56 | Histopathological effect of pterostilbene as chemoprevention in N-nitroso-tri-chloroethylurea (NTCU)-induced lung squamous cell carcinoma (SCC) mouse model. ( Ghazali, AR; Masre, SF; Surien, O, 2020) |
| "Considering the carcinogenesis model, we conclude that 2 or 4 weeks of N-nitroso-tris-chloroethylurea treatment may be suitable for investigating new chemicals for promotional or suppressive effects on lung squamous cell carcinoma." | 1.39 | Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice. ( Fujioka, M; Ishii, N; Kakehashi, A; Kitano, M; Tago, Y; Wanibuchi, H; Wei, M; Yamano, S, 2013) |
| "The experimental model of cortical dysplasia (CD) obtained by administering carmustine (1-3-bis-chloroethyl-nitrosurea [BCNU]) in pregnant rat uterus mimics the histopathological abnormalities observed in human CD patients: altered cortical layering, and presence of heterotopia and dysmorphic/heterotopic neurons." | 1.35 | Expression of layer-specific markers in the adult neocortex of BCNU-Treated rat, a model of cortical dysplasia. ( Frassoni, C; Inverardi, F; Moroni, RF; Regondi, MC; Spreafico, R; Watakabe, A; Yamamori, T, 2009) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 1.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Cyclocreatine was not very cytotoxic upon 24 h of exposure of human SW2 small-cell lung cancer cells to concentrations of up to 5 mM." | 1.29 | Cyclocreatine in cancer chemotherapy. ( Kaddurah-Daouk, R; Kufe, DW; Liu, J; Menon, K; Northey, D; Teicher, BA, 1995) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| " Two doses of carmustine at intervals of one week could eradicate the disease even during the phase of logarithmic growth of the leukaemic cells, this result depending upon the level of treatment and time of dosing post-inoculation with leukaemic cells." | 1.27 | Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia. ( Bock, M; Jackson, H; Jackson, NC; Lendon, M, 1984) |
| "Two human brain tumors which were previously established in nude mice were used to determine antitumor efficacy of various therapeutic agents." | 1.27 | Human brain tumor xenografts in nude mice as a chemotherapy model. ( Houchens, DP; Ovejera, AA; Riblet, SM; Slagel, DE, 1983) |
| "A combination chemotherapy regimen for brain tumors was developed, based on investigations of the survival of animals harboring the intracerebral 9L rat brain-tumor model and on analyses of their clonogenic tumor cells." | 1.27 | Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil. ( Dougherty, DV; Gerosa, MA; Rosenblum, ML; Wilson, CB, 1983) |
| " We have evaluated the dose-response curve for the i." | 1.27 | Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. ( Bigner, DD; Bigner, SH; Bullard, DE, 1985) |
| "Schmidt-Ruppin strain of Rous Sarcoma was inoculated intracerebrally into 27 newborn beagle dogs." | 1.26 | BCNU and steroids in the viral-induced dog brain tumor. ( Brisman, R; Gamboa, E; Goldberg, N; Hilal, S; Michelsen, JW; Schlesinger, EB; Willson, N, 1979) |
| " A comparison of the in vitro colony-forming capacity of treated and untreated tumor cells permits calculation of the fraction of clonogenic tumor cells surviving in vivo therapy; The plateau that we previously observed o the BCNU dose-response curve is not the result of repair of potentially lethal damage, since no change in the 0." | 1.26 | Brain-tumor therapy. Quantitative analysis using a model system. ( Knebel, KD; Rosenblum, MK; Vasquez, DA; Wilson, CB, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (44.93) | 18.7374 |
| 1990's | 7 (10.14) | 18.2507 |
| 2000's | 10 (14.49) | 29.6817 |
| 2010's | 18 (26.09) | 24.3611 |
| 2020's | 3 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zakaria, MA | 1 |
| Rajab, NF | 1 |
| Chua, EW | 1 |
| Selvarajah, GT | 1 |
| Masre, SF | 2 |
| Surien, O | 1 |
| Ghazali, AR | 1 |
| Azzalin, A | 1 |
| Nato, G | 1 |
| Parmigiani, E | 1 |
| Garello, F | 1 |
| Buffo, A | 1 |
| Magrassi, L | 1 |
| Hayes, CD | 1 |
| Dey, D | 1 |
| Palavicini, JP | 1 |
| Wang, H | 1 |
| Patkar, KA | 1 |
| Minond, D | 1 |
| Nefzi, A | 1 |
| Lakshmana, MK | 1 |
| Qian, L | 1 |
| Zheng, J | 1 |
| Wang, K | 1 |
| Tang, Y | 1 |
| Zhang, X | 1 |
| Zhang, H | 1 |
| Huang, F | 1 |
| Pei, Y | 1 |
| Jiang, Y | 2 |
| Tago, Y | 2 |
| Yamano, S | 2 |
| Wei, M | 1 |
| Kakehashi, A | 1 |
| Kitano, M | 1 |
| Fujioka, M | 2 |
| Ishii, N | 2 |
| Wanibuchi, H | 2 |
| Moroni, RF | 7 |
| Inverardi, F | 7 |
| Regondi, MC | 7 |
| Pennacchio, P | 3 |
| Spreafico, R | 5 |
| Frassoni, C | 7 |
| Song, JM | 1 |
| Qian, X | 1 |
| Teferi, F | 1 |
| Pan, J | 1 |
| Wang, Y | 1 |
| Kassie, F | 1 |
| Ghosh, M | 1 |
| Dwyer-Nield, LD | 1 |
| Kwon, JB | 1 |
| Barthel, L | 1 |
| Janssen, WJ | 1 |
| Merrick, DT | 2 |
| Keith, RL | 2 |
| Noé, F | 1 |
| Gnatkovsky, V | 1 |
| Zucca, I | 3 |
| de Curtis, M | 1 |
| Hu, M | 1 |
| Kramer, B | 1 |
| Zhang, GY | 1 |
| Wang, YM | 1 |
| Watson, D | 1 |
| Howden, B | 1 |
| McCowage, G | 1 |
| Alexander, IE | 1 |
| Gunning, P | 1 |
| Alexander, SI | 1 |
| Gi, M | 1 |
| Doi, K | 1 |
| Okada, S | 1 |
| Hirayama, Y | 1 |
| Tachibana, H | 1 |
| Tatsumi, K | 1 |
| Liu, C | 2 |
| Yao, S | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Mathios, D | 1 |
| Kim, JE | 1 |
| Mangraviti, A | 1 |
| Phallen, J | 1 |
| Park, CK | 1 |
| Jackson, CM | 1 |
| Garzon-Muvdi, T | 1 |
| Kim, E | 1 |
| Theodros, D | 1 |
| Polanczyk, M | 1 |
| Martin, AM | 1 |
| Suk, I | 1 |
| Ye, X | 1 |
| Tyler, B | 1 |
| Bettegowda, C | 1 |
| Brem, H | 2 |
| Pardoll, DM | 1 |
| Lim, M | 1 |
| Kang, GS | 1 |
| Wang, XD | 1 |
| Mohler, ML | 1 |
| Kirichenko, OV | 1 |
| Patil, R | 1 |
| Orr, WE | 1 |
| Miller, DD | 1 |
| Geisert, EE | 1 |
| Amarasingh, S | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 1 |
| Watakabe, A | 1 |
| Yamamori, T | 1 |
| Recinos, VR | 1 |
| Tyler, BM | 1 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 1 |
| Cipelletti, B | 1 |
| Mastropietro, A | 1 |
| Hudish, TM | 1 |
| Opincariu, LI | 1 |
| Mozer, AB | 1 |
| Johnson, MS | 1 |
| Cleaver, TG | 1 |
| Malkoski, SP | 1 |
| Chikhladze, M | 1 |
| Donzelli, A | 1 |
| Corradini, I | 1 |
| Braida, D | 1 |
| Sala, M | 1 |
| Franceschetti, S | 1 |
| Benardete, EA | 1 |
| Kriegstein, AR | 1 |
| Pineda, B | 1 |
| Estrada-Parra, S | 1 |
| Pedraza-Medina, B | 1 |
| Rodriguez-Ropon, A | 1 |
| Pérez, R | 1 |
| Arrieta, O | 1 |
| Murphy, S | 2 |
| Boyle, FM | 1 |
| Davey, RA | 1 |
| Gu, XQ | 1 |
| Mather, LE | 1 |
| Uyanikgil, Y | 1 |
| Baka, M | 1 |
| Ateş, U | 1 |
| Turgut, M | 1 |
| Yavaşoğlu, A | 1 |
| Ulker, S | 1 |
| Sözmen, EY | 1 |
| Sezer, E | 1 |
| Elmas, C | 1 |
| Yurtseven, ME | 1 |
| Panzica, F | 1 |
| Schold, SC | 2 |
| Bigner, DD | 5 |
| Jackson, H | 1 |
| Jackson, NC | 1 |
| Bock, M | 1 |
| Lendon, M | 1 |
| Yoshida, T | 1 |
| Shimizu, K | 1 |
| Ushio, Y | 1 |
| Hayakawa, T | 1 |
| Mogami, H | 1 |
| Nakata, Y | 1 |
| Sakamoto, Y | 1 |
| Houchens, DP | 1 |
| Ovejera, AA | 1 |
| Riblet, SM | 1 |
| Slagel, DE | 1 |
| Gerosa, MA | 2 |
| Dougherty, DV | 2 |
| Wilson, CB | 3 |
| Rosenblum, ML | 2 |
| Fiebig, HH | 2 |
| Strobel, H | 1 |
| Schmähl, D | 2 |
| Schwartz, GN | 1 |
| Biegel, JA | 1 |
| Boggs, SS | 1 |
| Drago, JR | 1 |
| Worgul, TJ | 1 |
| Gallagher, C | 1 |
| Spence, AM | 1 |
| Geraci, JP | 1 |
| Wheeler, KT | 1 |
| Kaufman, K | 1 |
| Bullard, DE | 2 |
| Bigner, SH | 2 |
| Steinbok, P | 1 |
| Mahaley, MS | 2 |
| U, R | 1 |
| Varia, MA | 1 |
| Lipper, S | 1 |
| Mahaley, J | 1 |
| Dalzell, JG | 1 |
| Kimler, BF | 2 |
| Teicher, BA | 1 |
| Menon, K | 1 |
| Northey, D | 1 |
| Liu, J | 1 |
| Kufe, DW | 1 |
| Kaddurah-Daouk, R | 1 |
| Arroyo, MH | 1 |
| Refojo, MF | 1 |
| Araiz, JJ | 1 |
| Tolentino, FI | 1 |
| Cajita, VN | 1 |
| Elner, VM | 1 |
| Evans, RG | 1 |
| Morantz, RA | 1 |
| Chen, ZP | 2 |
| Wang, G | 1 |
| Huang, Q | 1 |
| Sun, ZF | 1 |
| Zhou, LY | 1 |
| Wang, AD | 1 |
| Panasci, LC | 2 |
| Lee, A | 1 |
| DeJong, G | 1 |
| Guo, J | 1 |
| Bu, X | 1 |
| Jia, WW | 1 |
| Wang, ZM | 1 |
| Carter, CA | 1 |
| Alley, MC | 1 |
| Mohr, G | 1 |
| Finklestein, JZ | 1 |
| Tittle, K | 1 |
| Rubenstein, J | 1 |
| Meshnik, R | 1 |
| Weiner, J | 1 |
| Gentry, RE | 1 |
| Brisman, R | 1 |
| Schlesinger, EB | 1 |
| Willson, N | 1 |
| Hilal, S | 1 |
| Michelsen, JW | 1 |
| Gamboa, E | 1 |
| Goldberg, N | 1 |
| Murphy, SG | 1 |
| LoBuglio, AF | 1 |
| Chirigos, MA | 1 |
| Schultz, RM | 1 |
| Rosenblum, MK | 1 |
| Knebel, KD | 1 |
| Vasquez, DA | 1 |
| Zeller, WH | 1 |
| Hiramoto, R | 1 |
| Ghanta, V | 1 |
| Durant, JR | 1 |
| Lynch, RG | 1 |
| Medoff, G | 1 |
| Valeriote, F | 1 |
| Bradford, R | 2 |
| Darling, JL | 2 |
| Sier, N | 1 |
| Thomas, DG | 2 |
| Abernathey, CD | 1 |
| Kooistra, KL | 1 |
| Wilcox, GL | 1 |
| Laws, ER | 1 |
| Bamberg, M | 1 |
| Budach, V | 1 |
| Stuschke, M | 1 |
| Gerhard, L | 1 |
| Loth, TS | 1 |
| Eversmann, WW | 1 |
| Schabel, FM | 2 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Laster, WR | 1 |
| Cheeks, JB | 1 |
| Frei, E | 1 |
| Goldin, A | 2 |
| Straus, MJ | 1 |
| Choi, SC | 1 |
| Shapiro, WR | 1 |
1 review available for carmustine and Disease Models, Animal
| Article | Year |
|---|---|
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Drug Evaluation; Gli | 2009 |
68 other studies available for carmustine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
NTCU induced pre-malignant and malignant stages of lung squamous cell carcinoma in mice model.
Topics: Animals; Biomarkers, Tumor; Carcinogens; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; C | 2021 |
Histopathological effect of pterostilbene as chemoprevention in N-nitroso-tri-chloroethylurea (NTCU)-induced lung squamous cell carcinoma (SCC) mouse model.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Carmustine; Disease Models, Animal; Fema | 2020 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.
Topics: Alzheimer Disease; Animals; Antineoplastic Agents, Alkylating; Brain; Carmustine; CHO Cells; Criceti | 2013 |
Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cations; | 2013 |
Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Carcinogenesis; Carcinoma, Squamous Cell; Carmustine; Cytoch | 2013 |
Genesis of heterotopia in BCNU model of cortical dysplasia, detected by means of in utero electroporation.
Topics: Animals; Axons; Carmustine; Cell Differentiation; Cell Movement; Disease Models, Animal; Electropora | 2013 |
Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice.
Topics: Animals; Carcinoma, Squamous Cell; Carmustine; Cytokines; Diet; Disease Models, Animal; Female; Gene | 2015 |
Tracheal dysplasia precedes bronchial dysplasia in mouse model of N-nitroso trischloroethylurea induced squamous cell lung cancer.
Topics: Animals; Biomarkers, Tumor; Bronchi; Carcinoma, Squamous Cell; Carmustine; Cell Transformation, Neop | 2015 |
Increased pCREB expression and the spontaneous epileptiform activity in a BCNU-treated rat model of cortical dysplasia.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Brain; Calbindins; Carmustine; CREB-Binding | 2015 |
Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Carmustine; Disease Models, | 2015 |
Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Carmustine; Disease Models, Animal; Disease Progress | 2016 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Expression of layer-specific markers in the adult neocortex of BCNU-Treated rat, a model of cortical dysplasia.
Topics: Animals; Carmustine; Disease Models, Animal; DNA-Binding Proteins; Female; Gene Expression Regulatio | 2009 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Development of cortical malformations in BCNU-treated rat, model of cortical dysplasia.
Topics: Animals; Animals, Newborn; Carmustine; Cell Differentiation; Cell Movement; Disease Models, Animal; | 2011 |
In vivo detection of cortical abnormalities in BCNU-treated rats, model of cortical dysplasia, using manganese-enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Image Enhancement; I | 2011 |
N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice.
Topics: Administration, Topical; Animals; Bronchial Neoplasms; Carcinogens; Carcinoma, Squamous Cell; Carmus | 2012 |
Cytoarchitectural, behavioural and neurophysiological dysfunctions in the BCNU-treated rat model of cortical dysplasia.
Topics: Animals; Carmustine; Cognition; Disease Models, Animal; Entorhinal Cortex; Excitatory Postsynaptic P | 2013 |
Increased excitability and decreased sensitivity to GABA in an animal model of dysplastic cortex.
Topics: Animals; Bicuculline; Carmustine; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; Ele | 2002 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
Topics: Animals; Animals, Newborn; Brain Diseases; Bromodeoxyuridine; Carmustine; Cerebellar Cortex; Disease | 2007 |
Altered spatial distribution of PV-cortical cells and dysmorphic neurons in the somatosensory cortex of BCNU-treated rat model of cortical dysplasia.
Topics: Animals; Animals, Newborn; Antibodies; Calbindins; Carmustine; Classical Lissencephalies and Subcort | 2008 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia.
Topics: Animals; Carmustine; Disease Models, Animal; Female; Leukemia, Lymphoid; Male; Meningeal Neoplasms; | 1984 |
[Meningeal gliomatosis models as a chemosensitivity assay system].
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Survival; Disease Models, Animal; Dr | 1984 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Male; Rats; Rats, Inbred | 1983 |
Experimental chemotherapy with N'N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) in autochthonous neurogenic tumors of the rat transplacentally induced by ethylnitrosourea.
Topics: Animals; Carmustine; Disease Models, Animal; Ethylnitrosourea; Female; Fetus; Maternal-Fetal Exchang | 1982 |
A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Germanium; Karyotyping; Leukemia, Experiment | 1982 |
Castration--chemotherapy treatment of prostate cancer model.
Topics: Animals; Carmustine; Castration; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Disea | 1981 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
Efficacy of continuous treatment with radiation in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Male; Neoplasms, Experimental; Radiati | 1981 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carmustine; C | 1994 |
Cyclocreatine in cancer chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Carmustine; Cell Division; Ce | 1995 |
Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy.
Topics: Animals; Carmustine; Cells, Cultured; Conjunctiva; Disease Models, Animal; Drug Carriers; Drug Deliv | 1993 |
Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ca | 1993 |
Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Topics: Animals; Antineoplastic Agents; Carmustine; Carrier Proteins; Disease Models, Animal; Drug Screening | 1999 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Carmustine; Carrier Proteins; Disease Models, Animal; Gene Expressio | 2001 |
Combination chemotherapy in murine neuroblastoma.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Disease Models, Animal; Dox | 1976 |
Immunobiology of primary intracranial tumors.
Topics: Alpharetrovirus; Animals; Astrocytoma; BCG Vaccine; Brain Neoplasms; Carmustine; Disease Models, Ani | 1977 |
BCNU and steroids in the viral-induced dog brain tumor.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Disease Models, Animal; | 1979 |
L2C leukemia: a model of human acute leukemia.
Topics: Age Factors; Animals; BCG Vaccine; Carmustine; Central Nervous System Diseases; Cerebral Ventricle N | 1977 |
Animal models in cancer research which could be useful in studies of the effect of alcohol on cellular immunity.
Topics: Adrenal Cortex Hormones; Alcoholism; Animals; Carmustine; Disease Models, Animal; Humans; Immunity, | 1979 |
L2C guinea pig leukemia. A potential model for structuring multimodality therapy.
Topics: Animals; BCG Vaccine; Carmustine; Cyclophosphamide; Disease Models, Animal; Female; Freund's Adjuvan | 1978 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
An experimental model for meningeal leukemia in rats (L5222). Effect of treatment with BCNU and cyclophosphamide.
Topics: Animals; Brain Neoplasms; Carmustine; Cyclophosphamide; Disease Models, Animal; Drug Evaluation, Pre | 1976 |
Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line; Cell Survival; Cyclophosphamide; Disease Mode | 1975 |
A murine model for central nervous system leukemia and its possible relevance to human leukemia.
Topics: Amphotericin B; Animals; Brain; Carmustine; Central Nervous System Diseases; Disease Models, Animal; | 1975 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma; Hu | 1988 |
Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas.
Topics: Animals; Astrocytoma; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Lethal D | 1988 |
Treatment methods for extravasations of chemotherapeutic agents: a comparative study.
Topics: Animals; Antidotes; Antineoplastic Agents; Carmustine; Dactinomycin; Debridement; Disease Models, An | 1986 |
Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Carotid Arteries; Disease Models, Animal; Injections, Intra-Ar | 1985 |
Combination chemotherapy for spontaneous AKR lymphoma.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Increased lifespan with altered sequence of administration of BCNU and cytoxan in L1210 leukemic mice.
Topics: Animals; Ascites; Carmustine; Cyclophosphamide; Disease Models, Animal; Leukemia L1210; Male; Mice; | 1973 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |